OncoMatch/Clinical Trials/NCT04700332

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Is NCT04700332 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies DCFPyL PET/CT for prostate cancer.

Phase 2RecruitingHoag Memorial Hospital PresbyterianNCT04700332Data as of May 2026

Treatment: DCFPyL PET/CT — The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Hoag Memorial Hospital Presbyterian · Irvine, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify